Protagonist Therapeutics (PTGX) Shares Outstanding (Weighted Average) (2015 - 2026)

Protagonist Therapeutics has disclosed Shares Outstanding (Weighted Average) across 8 years of filings, most recently posting $65.1 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $65.1 million, up 3.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.1 million (up 3.37% YoY), and the FY2025 annual result was $63.6 million, up 3.26% from the prior year.
• Shares Outstanding (Weighted Average) came in at $65.1 million for Q1 2026 at Protagonist Therapeutics, up from $63.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $65.1 million in Q1 2026 to a low of $48.8 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $61.0 million (2024), against an average of $57.9 million.
• Across the five-year window, Shares Outstanding (Weighted Average) climbed 20.33% in 2024 and increased 2.67% in 2025, its largest moves.
• Protagonist Therapeutics' Shares Outstanding (Weighted Average) stood at $49.1 million in 2022, then gained by 15.59% to $56.8 million in 2023, then grew by 8.46% to $61.6 million in 2024, then gained by 3.26% to $63.6 million in 2025, then climbed by 2.38% to $65.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $65.1 million (Q1 2026), $63.6 million (Q4 2025), and $63.4 million (Q3 2025), per Business Quant data.